

Special Issue

Microcirculation, Thrombosis, and Inflammation in Peripheral Artery Disease and in the Brain

Message from the Guest Editors

Peripheral artery disease is, to a wide extent, driven by chronic inflammatory and prothrombotic signaling pathways. Vascular dysfunction underlies the progression of atherosclerosis and macrovascular as well as microvascular alterations. Moreover, pro-inflammatory signaling pathways are supposed to be a link between atherosclerotic and neuropsychological diseases. The difference is that in neuroinflammation, no broad invasion into tissue or tissue destruction takes place. Instead, functional connectivity problems or neurotransmitter alterations, for example, lead to clinically similar pictures as psychic alterations due to artery disease. This Special Issue invites us to dig into the biomedical exploration of these differentiations and enrich the bio-psycho connection. We welcome articles focusing on peripheral artery disease, including vascular dysfunction, thrombosis, and inflammation, with a special focus on the context of systemic secretion of chemokines and neurotransmitter alterations.

Guest Editors

Dr. Patricia Pia Wadowski

Department of Internal Medicine II, Division of Angiology, Medical University of Vienna, 1090 Wien, Austria

Dr. Henriette Löffler-Stastka

Department of Psychoanalysis and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/202460

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).